Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome

作者：Zhi Liu, Hengjian Hao, Chunlin Yin, Yanyan Chu, Jing Li, Dong Xu · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.15078 · 被引用次数：24 · 研究领域：Lipoproteins and Cardiovascular Health、Health Systems, Economic Evaluations, Quality of Life、Computational Drug Discovery Methods

// Zhi Liu 1 , Hengjian Hao 1 , Chunlin Yin 1 , Yanyan Chu 1 , Jing Li 1 and Dong Xu 1 1 Division of Cardiology, Xuanwu Hospital Capital Medical University, Beijing, China Correspondence to: Dong Xu, email: // Jing Li, email: // Keywords : elderly; acute coronary syndrome; atorvastatin; ezetimibe; prognosis Received : October 05, 2016 Accepted : January 08, 2017 Published : February 03, 2017 Abstract Objective Compared the effect of atorvastatin 10 mg combined ezetimibe 10 mg therapy with atorvastatin 20 mg on the long-term outcomes in very elderly patients with acute coronary syndrome. Methods A total of 230 octogenarian patients with acute coronary syndrome underwent coronary angiography were randomized to combined therapy group (atorvastatin 10 mg/d and ezetimibe 10 mg/d, n=114) or double-dose atorvastatin group (atorvastatin 20mg/d, n=116). The primary end point was one-year incidence of major adverse cardiovascular events (including cardiac death, spontaneous myocardial infarction, unplanned revascularization). Result At the end of one year, the percentage of patients with low-density lipoprotein cholesterol level decreased more than 30% or 50% were comparable between the two groups (93.5% vs. 90.1%, p= 0.36; 54.6% vs. 49.6%, p= 0.45). The rate of major adverse cardiovascular events in combined therapy group was similar with double-dose atorvastatin group (23.2% vs. 19.8%, p=0.55). In COX regression model, the risk of major adverse cardiovascular events in combined group...